Company Announcements

Notification of Dilution of Voting Rights

Source: RNS
RNS Number : 4464V
Hutchison China Meditech Limited
14 April 2021

Notification of Dilution of Voting Rights


Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 14, 2021:  Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited ("CK Hutchison") shareholding[1] in HUTCHMED remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of HUTCHMED ("Shares"). 


Each American Depositary Share ("ADS") represents five Shares.  As announced on April 8, 2021, HUTCHMED issued a total of 16,393,445 Shares (equivalent to 3,278,689 ADSs) to funds affiliated with Baring Private Equity Asia.  HUTCHMED was notified on April 14, 2021 that this issuance diluted CK Hutchison's holding[1] to 44.66 per cent of the total number of voting rights of HUTCHMED.  The date on which the notification threshold was crossed was April 14, 2021.


[1] Held through CK Hutchison's indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.





HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company.  It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: or follow us on LinkedIn.





Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile)

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.